However, a GAL‐3 inhibitor (GR‐MD‐02), in combination with pembrolizumab or an anti‐CTLA4 inhibitor, is being currently evaluated for the treatment of patients with metastatic NSCLC, melanoma and squamous cell head and neck cancer patients (NCT02575404) highlighting that GAL‐3 could be part of a panel of biomarkers that predicts the outcome for immunotherapy in NSCLC [72]. This evidence concerns the gene LGALS3 and non-small cell lung carcinoma.